The UK and US have reached a key commercial pact that will maintain zero duties on UK drug exports entering the US market.
Key Provisions of the Pact
Under the terms of the agreement, the UK has committed to increase funding on drugs through the NHS. This commitment secures that tariffs on these crucial products will remain at zero for a timeframe of three years.
This development comes after previous threats to hike import taxes on branded pharmaceutical products, with potential rates mentioned up to 100%.
"This agreement between the Britain strengthens the international landscape for new treatments and establishes much-needed balance to transatlantic drug exports," a statement declared.
Commercial Importance
Pharmaceuticals represent one of the UK's most significant export categories to the United States, which is by far the largest market for large companies like GSK and AstraZeneca.
Export figures show that in the year to the end of last September, the UK sold medicines worth £11.1bn to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This guarantee safeguards jobs, boosts investment and facilitates the UK to become a worldwide center for biotech and pharma," a government official commented.
Specific UK Commitments
The agreement involves several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase overall NHS spending on drugs from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The sum drug companies must refund to the NHS to control costs will be limited at 15%. Last year, refunds were more than 20%.
Industry Background
The deal follows a protracted row between the sector and the ministers over medicine costs and approval rates.
This friction were exacerbated by arguments that American customers were paying significantly more for the identical medicines than people in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar funding commitments have been announced toward projects in the United States.
A senior figure stated that the NHS needed to spend more on treatments, noting that its expenditure on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
